ArticleFrontiers in cellular and infection microbiology2021
The Level of D-Dimer Is Positively Correlated With the Severity of
Article in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 69 citations in OpenAlex.
- Assessment of predictive efficacy for prognosis of pediatric severeTranslational pediatrics · 2026Article
- Risk factors for plastic bronchitis complicating severeTranslational pediatrics · 2026Article
- S100A8/A9 as a novel predictor for severe Mycoplasma pneumoniae pneumonia in children: A prospective observational study.Clinics (Sao Paulo, Brazil) · 2026Article
- Application of Clinical Indicators in the Early Prediction of RefractoryClinical pediatrics · 2026Article
- Development and validation of a multivariate predictive model for the risk of refractory mycoplasma pneumoniae pneumonia in children based on quantitative computed tomography features.Translational pediatrics · 2026Article
- Advances in treatment and prevention of pulmonary thromboembolism associated with Mycoplasma pneumoniae pneumonia in children.Pediatric research · 2026Review
- High-Risk CCL14 lineage drives severe Mycoplasma pneumoniae pneumonia in children: a study in central China.Clinical and experimental pediatrics · 2026Article
- Clinical risk factors and predictive value of thin-section CT for bronchial mucus plugs in pediatric mycoplasma pneumoniae pneumonia.BMC infectious diseases · 2026Article
- Impact of Allergic Diseases or Obstructive Sleep Apnea Risk on SevereJournal of clinical medicine · 2026Article
- Risk factors and clinical characteristics of fulminant Mycoplasma pneumoniae pneumonia in children: a retrospective case‒control study.BMC infectious diseases · 2026Article
- Immunopathogenesis, molecular phenotyping, and host-directed interventions for severe pediatricFrontiers in cellular and infection microbiology · 2026Review
- Integrative Traditional Chinese Medicine Strategies for Refractory Mycoplasma Pneumonia in Children: Clinical Challenges, Mechanisms, and Evidence-Based Insights.Infection and drug resistance · 2026Review
- The Role of NLR and Ferritin Levels as Biomarkers for Corticosteroid Dosage in Children with RefractoryJournal of inflammation research · 2026Article
- Comparative clinical response, safety, and institutional drug use efficiency of intravenous azithromycin versus erythromycin in pediatricFrontiers in cellular and infection microbiology · 2026Article
- Clinical Characteristics ofInfection and drug resistance · 2026Article
- Exploring Clinical Characteristics and Risk Factors ofJournal of inflammation research · 2026Article
- Influence of Mycoplasma Resistance Genes on Pediatric Mycoplasma Pneumonia Treatment and Determinants for Second-line Antimicrobial Adjustment.Combinatorial chemistry & high throughput screening · 2026Article
- Clinical features and risk factors of plastic bronchitis in Mycoplasma pneumoniae pneumonia children with pulmonary consolidation: a prospective cohort study.Frontiers in pediatrics · 2026Article
- Development of a Prediction Model for Severe PediatricInfection and drug resistance · 2026Article
- Prediction models for refractoryFrontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Methods: Retrospective analysis was conducted on 356 patients who were hospitalized in our hospital for MPP between January 1, 2017, and December 31, 2019. According to the peak value of D-dimer, patients were divided into three groups: the normal group (D-dimer<0.55 mg/L), the mild-moderately elevated group (D-dimer 0.55-5.5 mg/L) and the severely elevated group (D-dimer >5.5 mg/L). The demographic and clinical information, radiological findings, laboratory data, and treatments of patients were compared among different groups. Results: 106 patients were in the normal group, 204 patients were in the mild-moderately elevated group, and 46 patients were in the severely elevated group. More severe clinical and radiographic manifestations, longer length of fever, hospital stay and antibiotic therapy duration, higher incidences of extra-pulmonary complications, refractory MPP (RMPP), severe MPP (SMPP) were found in the elevated group, when compared with the normal group ( Conclusions: MPP patients with higher levels of D-dimer had more severe clinical manifestations and needed longer duration of treatment, which might be closely related to the severity of lung inflammation after MP infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.